Literature DB >> 9178464

Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): composition, structure and immunogenicity.

D Diminsky1, R Schirmbeck, J Reimann, Y Barenholz.   

Abstract

The composition, structure and immunogenicity of hepatitis B surface antigen (HBsAg) particles derived from Chinese hamster ovary (CHO) cells and from cells of the yeast Hansenula polymorpha were compared. The particles were similar in size distribution (mean 20-33 nm), in shape (spherical), in gross composition (protein to lipid weight ratio of 60:40), and in types of lipids (phospholipids > > sterols = sterol esters = triacylglycerols). Differences related to genetic engineering and type of host cells were found in peptide and lipid compositions. CHO-HBsAg has three peptides: S, M and L, each in two forms of glycosylation, while the Hansenula-HBsAg has only the nonglycosylated S peptide. The electrical surface potential at the lipid/water interface of HBsAg derived from Hansenula is more negative than that of HBsAg derived from CHO, which was close to neutrality. Although the numbers of cysteine residues (all in the S peptides) are identical (14), 11 of them are free thiols in the CHO-HBsAg, compared with three to four in the Hansenula-HBsAg. The fact that 85% of the phospholipids are hydrolyzed by phospholipase C and that all the aminophospholipids react with trinitrobenzenesulfate suggests that the particles derived from both cell types are either leaky vesicles or have a lipoprotein-like structure. Subcutaneous injection into mice of fluorescein-isothiocyanate-labeled HBsAg particles from both sources resulted in their accumulation in the marginal sinus of lymph nodes. The humoral responses to subcutaneous injection into mice of CHO- and Hansenula-HBsAg were similar: however, the cytotoxic T lymphocyte response to CHO-HBsAg was lower.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9178464     DOI: 10.1016/s0264-410x(96)00239-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  20 in total

1.  Hepatitis B small surface antigen particles are octahedral.

Authors:  Robert J C Gilbert; Lucy Beales; Donatienne Blond; Martha N Simon; Beth Y Lin; Francis V Chisari; David I Stuart; David J Rowlands
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-03       Impact factor: 11.205

2.  Biochemical and biophysical characterization of maize-derived HBsAg for the development of an oral vaccine.

Authors:  Shweta Shah; Celine A Hayden; Maria E Fischer; A Gururaj Rao; John A Howard
Journal:  Arch Biochem Biophys       Date:  2015-10-28       Impact factor: 4.013

3.  Immunogenicity and safety of Advax™, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study.

Authors:  David Gordon; Peter Kelley; Susanne Heinzel; Peter Cooper; Nikolai Petrovsky
Journal:  Vaccine       Date:  2014-09-27       Impact factor: 3.641

4.  Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro.

Authors:  Ted Bader; Brent Korba
Journal:  Antiviral Res       Date:  2010-03-06       Impact factor: 5.970

Review 5.  Advances in aluminum hydroxide-based adjuvant research and its mechanism.

Authors:  Peng He; Yening Zou; Zhongyu Hu
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  Domains of the Hepatitis B Virus Small Surface Protein S Mediating Oligomerization.

Authors:  Sascha Suffner; Nadine Gerstenberg; Maria Patra; Paula Ruibal; Ahmed Orabi; Michael Schindler; Volker Bruss
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

7.  Antibody response to revaccination among adult non-responders to primary Hepatitis B vaccination in China.

Authors:  Li Zhang; Jiaye Liu; Jingjing Lu; Bingyu Yan; Lizhi Song; Li Li; Fuqiang Cui; Guomin Zhang; Fuzhen Wang; Xiaofeng Liang; Aiqiang Xu
Journal:  Hum Vaccin Immunother       Date:  2015-08-07       Impact factor: 3.452

8.  Duck hepatitis B virus requires cholesterol for endosomal escape during virus entry.

Authors:  Anneke Funk; Mouna Mhamdi; Heinz Hohenberg; Jörg Heeren; Rudolph Reimer; Carsten Lambert; Reinhild Prange; Hüseyin Sirma
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

9.  A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing.

Authors:  Fadi Saade; Yoshikazu Honda-Okubo; Samay Trec; Nikolai Petrovsky
Journal:  Vaccine       Date:  2013-01-07       Impact factor: 3.641

Review 10.  Assembly and Release of Hepatitis B Virus.

Authors:  Lisa Selzer; Adam Zlotnick
Journal:  Cold Spring Harb Perspect Med       Date:  2015-11-09       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.